What is Phil?
Phil operates as a sophisticated software-driven therapy deployment platform designed to streamline the complex pharmaceutical landscape. By replacing legacy distribution models with integrated digital solutions, the company provides manufacturers with enhanced visibility into patient access, affordability, and market penetration. Its platform serves as a critical infrastructure layer, enabling seamless coordination between stakeholders and ensuring that patients receive timely, cost-effective access to essential therapies. Through its focus on digital-first patient services, Phil has established a defensible market position as a vital partner for life sciences organizations seeking to optimize their commercial operations.
How much funding has Phil raised?
Phil has raised a total of $176.1M across 6 funding rounds:
Other Financing Round
$2.1M
Series A
$10M
Series B
$25M
Series C
$23M
Series D
$56M
Debt
$60M
Other Financing Round (2015): $2.1M with participation from Forerunner Ventures, Eniac Ventures, Fabrice Grinda, FJ Labs, Uncork Capital, and Tom Williams
Series A (2017): $10M led by Eniac Ventures, Uncork Capital, Forerunner Ventures, Silicon Valley Bank, Transmedia Capital, Crosslink Capital, and Softtech VC
Series B (2019): $25M supported by Tarsadia Hotels, Uncork Capital, GreatPoint Energy, and Crosslink Capital
Series C (2021): $23M, investors not publicly disclosed
Series D (2021): $56M backed by Warburg Pincus
Debt (2025): $60M with participation from K2 HealthVentures
Key Investors in Phil
Forerunner Ventures
Forerunner Ventures partners with founders to build category-defining companies at the intersection of technology and human behavior, focusing on emerging trends that redefine customer experiences.
Uncork Capital
Uncork Capital is a seed-stage venture firm that commits early to startups, providing critical support and partnership to help companies navigate the challenges of early growth.
Crosslink Capital
Crosslink Capital is an investment firm that partners with ambitious early-stage founders, leveraging a proprietary network to build category-defining companies across North America.
What's next for Phil?
With the recent $60M in capital, Phil is well-positioned to accelerate its product roadmap and deepen its penetration within the healthcare ecosystem. The company's strategic trajectory suggests a focus on scaling its distribution models and enhancing its data-driven market access tools to meet the evolving demands of global pharmaceutical manufacturers. As the firm transitions into its next phase of growth, it is expected to leverage its robust investor network to explore new therapeutic categories and expand its footprint in the digital health market. The emphasis remains on driving operational efficiency and improving patient outcomes through technological excellence.
See full Phil company page
